Merck Announces Recipients of the Grant for Growth Innovation 2016

13-Sep-2016 - France

Merck announced the recipients of the Grant for Growth Innovation (GGI) for 2016. The awards were announced at an award presentation meeting organized by Merck during the 55th European Society for Pediatric Endocrinology (ESPE) Meeting in Paris, France.

Merck is providing grants to pioneers of new research in growth through the Grant for Growth Innovation award. Identifying and supporting forward thinking researchers in the field of growth follows Merck´s scientific strategy of providing a platform that makes innovation possible.

“It is inspiring to see the high quality and aspiration of the researchers to whom these grants have been awarded. We recognise that despite advances in treatment and management of growth disorders, we still require a better understanding of these diseases to address the high unmet medical need. We look forward to seeing the results of these projects.” said Dr Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at Merck´s Biopharma business.

38 applications were received from 20 countries and reviewed by an independent Scientific Steering Committee composed of five internationally renowned endocrinologists and researchers. Following a rigorous selection process, three awards were offered to innovative projects which seek to advance understanding in the field of growth. The winning projects are based in Australia, Italy and Brazil, and are as follows:

Andrew J. Brooks (University of Queensland Diamantina Institute, Brisbane, Australia); Project: Targeting the transmembrane domain of the growth hormone receptor to develop new drug classes addressing unmet needs in treatment of growth hormone disorders
Antonio Cittadini, MD, PhD (Federico II University, Naples, Italy); Project: Treatment of growth hormone deficiency associated with chronic heart failure: A randomized, double-blind, placebo-controlled study
Alexander Augusto de Lima Jorge, MD, PhD (University of São Paulo Medical School, Brazil); Project: Growth hormone and estrogen pharmacogenetics in patients with Turner syndrome

Merck initiated the GGI program to support the advancement of understanding of the field of growth. A total grant of up to €400,000 per year, divided between up to three research proposals, will be awarded to the selected projects. Each application is blinded and evaluated by an independent Scientific Steering Committee composed of internationally renowned endocrinologists and researchers, according to five criteria: innovation; scientific rationale; clarity; feasibility; and impact of research.

https://www.bionity.com/en/news/159691/merck-announces-recipients-of-the-grant-for-growth-innovation-2016.html